AZN Stock Forecast: AstraZeneca plc gains on urgent European demand for its COVID-19 vaccine

NASDAQ:AZN added 2.40% on Tuesday alongside a broader market rally.
Several European countries seek emergency use authorization for AstraZeneca’s COVID-19 vaccine.
AstraZeneca receives approvals for two additional non-COVID related drugs.

Stocks Reporter FXStreet

NASDAQ:AZN has now strung together consecutive days of gains as the stock trajectory continues to point upwards for the United Kingdom-based pharmaceutical giant. On Tuesday, AstraZeneca gained 2.40% to close the first trading session of the week at $52.57. While AstraZeneca has lagged behind its American rivals Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) in terms of widespread usage and distribution of its COVID-19 vaccine candidate, the old adage ‘it’s better late than never’ may be what its investors are currently thinking.

AstraZeneca received a further nod of approval from Europe when several countries including Austria, Greece and Denmark have urged the European Medicines Agency to fast track approvals for its vaccine. Austria, in particular, is battling rising cases of the virus, and have officially extended its lockdown to February 7th. The EMA did agree to review the AstraZeneca vaccine data on an expedited basis this month, so these countries should have their answer by the end of January.

AZN stock news

In other news, AstraZeneca has received approvals for its gastric-cancer treatment Enhertu, which it has developed in partnership with Japanese pharmaceutical firm Daiichi Sankyo, after its Phase II results were extremely positive. Enhertu represents the first new treatment for metastatic HER-2 gastric cancer in over a decade. AstraZeneca also received approval to release a new dosage for its non-small cell lung cancer treatment, Imfinzi, which will drastically cut back on patient medical visits, which is especially crucial during the COVID-19 pandemic. The new regiment will see Imfinzi provided to patients in a four-week dosage interval, which represents about half of the visits patients need to make on the current schedule.

Author

Stocks Reporter

FXStreet

GBP/USD extends the drop to 1.3360

GBP/USD builds on Monday’s decline and briefly clinches five-day lows near 1.3360 on Tuesday. Cable’s extra pullback follows the better tone in the Greenback as uncertainty in the Middle East prompts investors to adopt a cautious stance. Meanwhile, an apathetic UK labour market report also collaborates with the selling pressure on the British Pound.

EUR/USD stays offered just above 1.1400

EUR/USD keeps the downtrend well in place for yet another day, challenging the 1.1400 contention zone on Tuesday. The continuation of the selling impulse in spot comes amid decent gains in the US Dollar, which continues to find support in the persistent effervescence surrounding the US-Iran crisis.

Middle East crisis intensifies, Gold up

Gold now seems to have embarked on a consolidative phase below the key $4,100 mark per troy ounce in the latter part of Tuesday’s session. Meanwhile, uncertainty surrounding the Middle East conflict and rising expectations for a hawkish Fed policy outlook are expected to limit the precious metal’s bullish momentum in the near term.

XRP rebounds on rising on-chain activity

Ripple (XRP) ticks up and trades around $1.13 at the time of writing on Tuesday. This rebound aligns with a broader recovery in the cryptocurrency market, attributed to reports that mediators between the United States (US) and Iran are seeking a 10-day cessation of strikes to find a way back to the signed Memorandum of Understanding (MoU).

The Iranian war has again risen

The Iranian war has again risen to the top of the economics factor list. There is no end in sight. Intelligence experts say the current level of offense/retaliation will not change minds in Tehran, while in Washington, Trump fears all-out war, which would mean boots on the ground.

US Dollar mid-year outlook: Exceptional currency, exceptional risks?

The US Dollar enters the second half of 2026 in a markedly different position from a year ago. The King currency has recovered, reflecting persistent US inflation, changing expectations for Fed policy, geopolitical tensions and renewed demand for defensive assets.